表紙
市場調查報告書

5-羥色胺受體6 (5-HT6,血清素受體6,HTR6) - 開發中產品分析

5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 358699
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
5-羥色胺受體6 (5-HT6,血清素受體6,HTR6) - 開發中產品分析 5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 62 Pages
簡介

5-HT6受體是5-HT受體的亞型,與內因性神經傳達物質血清素結合。5-HT6受體在老年癡呆症和其他類型的癡呆症、肥胖中都扮演著重要的角色。

本報告提供5-羥色胺受體6 (5-HT6,血清素受體6,HTR6)的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品
  • 階段不明的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Adamed Sp. z o.o.
  • Avineuro Pharmaceuticals, Inc.
  • Axovant Sciences Ltd.
  • Biotie Therapies Corp.
  • Galenea Corp.
  • H. Lundbeck A/S
  • Reviva Pharmaceuticals Inc.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2023TDB

Summary

According to the recently published report '5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019'; 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - The 5-HT6 receptor is a subtype of 5-HT receptor that binds the endogenous neurotransmitter serotonin. Blockade of 5-HT6 receptors showed to increase glutamatergic and cholinergic neurotransmission in brain, whereas activation enhances GABAergic signaling in a widespread manner. Antagonism of 5-HT6 receptors facilitates dopamine and norepinephrine release in the frontal cortex while stimulation has the opposite effect. 5-HT6 receptor plays an important role in Alzheimer's disease and other forms of dementia and obesity.

The report '5-Hydroxytryptamine Receptor 6 - Pipeline Review, H2 2019' outlays comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders and Respiratory which include indications Psychiatric Disorders, Alzheimer's Disease, Cognitive Disorders, Schizophrenia, Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Autism, Bipolar Disorder (Manic Depression), Dementia, Depression, Generalized Anxiety Disorder (GAD), Idiopathic Pulmonary Fibrosis, Major Depressive Disorder, Neurology, Obesity, Parkinson's Disease, Psychosis, Pulmonary Arterial Hypertension and Schizoaffective Disorder.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
  • The report reviews 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Overview
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Companies Involved in Therapeutics Development
  • Adamed Sp zoo
  • Alla Chem LLC
  • Avineuro Pharmaceuticals Inc
  • Celon Pharma SA
  • H. Lundbeck AS
  • HEC Pharm Co Ltd
  • Reviva Pharmaceuticals Inc
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Drug Profiles
  • ADN-1184 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ADN-2013 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ADN-3662 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AV-3208 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVN-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVN-211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVN-3205 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVN-322 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVN-492 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brilaroxazine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HEC-30654AcOH - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • idalopirdine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pirdinenserin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize 5-HT6 for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize 5-HT6 Receptor for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Dormant Products
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Discontinued Products
  • 5-Hydroxytryptamine Receptor 6 (5 HT6 or Serotonin Receptor 6 or HTR6) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 09, 2019: ChemRar Group of Companies announces the successful completion of the second phase of clinical trials of an innovative drug for the treatment of generalized anxiety disorder
  • Jun 03, 2019: Reviva Pharmaceuticals announces successful completion of pre-IND meeting with FDA on Brilaroxazine for the treatment of idiopathic pulmonary fibrosis
  • Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
  • Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
  • Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
  • Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
  • Sep 22, 2016: Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer's disease
  • Jul 07, 2016: Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)
  • May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
  • Apr 11, 2016: Lundbeck to Present Data on Idalopirdine at American Academy of Neurology
  • Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
  • Jul 01, 2015: Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist
  • Dec 14, 2014: AllaChem Completes Phase Ib/IIa Clinical Study with AV4025, an HCV NS5A Inhibitor
  • Nov 05, 2013: Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for RP5063
  • Oct 10, 2013: Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-on Treatment for Alzheimer's Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Adamed Sp zoo, H2 2019
  • Pipeline by Alla Chem LLC, H2 2019
  • Pipeline by Avineuro Pharmaceuticals Inc, H2 2019
  • Pipeline by Celon Pharma SA, H2 2019
  • Pipeline by H. Lundbeck AS, H2 2019
  • Pipeline by HEC Pharm Co Ltd, H2 2019
  • Pipeline by Reviva Pharmaceuticals Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Dormant Products, H2 2019 (Contd..3), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • `Number of Products by Stage and Mechanism of Actions, H2 2019
  • `Number of Products by Stage and Route of Administration, H2 2019
  • `Number of Products by Stage and Molecule Type, H2 2019
Back to Top